NCT03705429View on ClinicalTrials.gov

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Breast Neoplasms
Interventions
DRUG

TC-H x Paclitaxel (P) + Trastuzumab(T)

chemotherapy

Trial Locations (3)

N6A5W9

London Health Sciences Centre, London

K1H 8L6

The Ottawa Hospital, Ottawa

P7B 6V4

Thunder Bay Regional Health Sciences Centre, Thunder Bay

All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03705429 - A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter